成人悪性神経膠腫治療薬の世界市場レポート 2025年

成人悪性神経膠腫治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.4％で35億5,000万米ドルに成長します。予測期間の成長は、免疫療法の進歩、標的治療、バイオマーカーの発見、リキッドバイオプシーの応用、アクセス拡大プログラムなどに起因しています。予測期間における主な動向には、患者中心の医薬品開発、ファストトラックおよびブレークスルー指定、ドラッグデリバリーシステムの進歩、共同研究イニシアティブ、人工知能の統合などがあります。

脳腫瘍患者の増加傾向は、成人悪性神経膠腫治療薬市場の成長を促進する重要な要因になると予測されます。脳腫瘍は、通常の制御機構を回避した細胞の異常増殖と無制限な成長を特徴とする組織の異常な塊です。成人悪性神経膠腫は、脳腫瘍の特定のタイプであり、異常で制御不能な増殖パターンを示す細胞で構成されます。成人悪性神経膠腫の治療には通常、外科的処置、放射線療法、化学療法が組み合わされます。米国がん協会の2023年1月の報告書によると、この動向を示すように、脳および神経系のがんに関連する症例数は2023年には24,810件に増加し、2020年の23,890件から3.85％増加しました。このように、脳腫瘍の増加は成人悪性神経膠腫治療薬市場拡大の原動力となっています。

脳腫瘍調査に特化した政府資金の注入は、成人悪性神経膠腫治療薬市場の成長軌道を大きく前進させる構えです。政府資金とは、連邦、州、地方などさまざまなレベルの政府機関が、イニシアチブ、プログラム、プロジェクト、組織、個人に対して支出する財政支援を意味します。脳腫瘍調査に対する政府資金の配分は、成人悪性神経膠腫治療薬を前進させる大きな可能性を秘めています。この資金は、革新的な治療法の開発、ピリミジン合成を中心としたオーダーメイドの薬剤設計、希少疾病用医薬品の承認の迅速化に大きく役立ちます。例えば、2023年6月、オーストラリア保健・高齢者医療省は、オーストラリア脳腫瘍ミッション（Australian Brain Cancer Mission）を開始し、特に脳腫瘍の研究活動を支援することを目的とした1億3,666万米ドルの基金を拠出しました。このイニシアチブの主な目的は、生存率を倍増させ、退形成性星細胞腫を含む脳腫瘍患者の全体的な生活の質を高めることです。その結果、脳腫瘍研究に向けた政府の資金援助は、成人悪性神経膠腫治療薬市場を推進する極めて重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界成人悪性神経膠腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の成人悪性神経膠腫治療薬市場：成長率分析
• 世界の成人悪性神経膠腫治療薬市場の実績：規模と成長, 2019-2024
• 世界の成人悪性神経膠腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界成人悪性神経膠腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の成人悪性神経膠腫治療薬市場病気の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多形性膠芽腫
• 未分化星細胞腫
• 未分化乏突起膠腫
• 未分化乏突起星細胞腫
• その他のタイプ
• 世界の成人悪性神経膠腫治療薬市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 放射線治療
• その他の治療法
• 世界の成人悪性神経膠腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• がん・放射線治療センター
• その他のエンドユーザー
• 世界の成人悪性神経膠腫治療薬市場多形性膠芽腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準的な治療法
• 実験的治療法
• 世界の成人悪性神経膠腫治療薬市場、未分化星細胞腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法の選択肢
• 標的療法
• 世界の成人悪性神経膠腫治療薬市場、未分化オリゴデンドログリオーマのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• 併用療法
• 世界の成人悪性神経膠腫治療薬市場、未分化乏突起星細胞腫のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的介入
• 補助療法
• 世界の成人悪性神経膠腫治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• まれな神経膠腫
• 新たな治療法

第7章 地域別・国別分析

• 世界の成人悪性神経膠腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の成人悪性神経膠腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 成人悪性神経膠腫治療薬市場：競合情勢
• 成人悪性神経膠腫治療薬市場：企業プロファイル
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Allergan plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Novartis AG
• Bayer AG
• Merck & Co Inc.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Abbott Laboratories
• AstraZeneca plc
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• GT Medical Technologies Inc.
• Lupin Limited
• Mylan NV
• Sanofi SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 成人悪性神経膠腫治療薬市場2029：新たな機会を提供する国
• 成人悪性神経膠腫治療薬市場2029：新たな機会を提供するセグメント
• 成人悪性神経膠腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The field of adult malignant glioma therapeutics focuses on treating brain tumors that originate in the glial cells of the brain or spinal cord, particularly in adults. This encompasses various treatment options designed to enhance the quality of life and extend the survival of individuals affected by malignant gliomas.

The primary subtypes of adult malignant glioma therapeutics include glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme (GBM), known for its aggressive nature, involves rapid tumor growth and the infiltration of neighboring brain tissue, typically without distant organ metastasis. Therapeutic interventions in this domain encompass chemotherapy, targeted therapy, radiotherapy, and other modalities. These treatments are administered in various healthcare settings, including hospitals, specialty clinics, and cancer and radiation therapy centers.

The adult malignant glioma therapeutics market research report is one of a series of new reports from The Business Research Company that provides adult malignant glioma therapeutics market statistics, including adult malignant glioma therapeutics industry global market size, regional shares, competitors with a adult malignant glioma therapeutics market share, detailed adult malignant glioma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the adult malignant glioma therapeutics industry. This adult malignant glioma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.25 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches.

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence.

The upward trajectory in brain tumor cases is anticipated to be a significant driver in propelling the growth of the adult malignant glioma therapeutics market. Brain tumors represent anomalous masses of tissue characterized by the abnormal proliferation and unchecked growth of cells, circumventing the usual regulatory mechanisms. Adult malignant glioma, a specific type of brain tumor, comprises cells exhibiting abnormal and uncontrolled growth patterns. Treatment for adult malignant glioma typically involves a combination of surgical procedures, radiation therapy, and chemotherapy. Illustrating this trend, as per the American Cancer Society's January 2023 report, the number of cases related to brain and nervous system cancers escalated to 24,810 in 2023, demonstrating a notable 3.85% increase from 23,890 recorded in 2020. Thus, the mounting instances of brain tumors serve as a driving force behind the expansion of the adult malignant glioma therapeutics market.

The infusion of government funding dedicated to brain cancer research is poised to significantly propel the growth trajectory of the adult malignant glioma therapeutics market moving forward. Government funding entails financial support disbursed by governmental bodies at various levels-federal, state, or local-towards initiatives, programs, projects, organizations, or individuals. The allocation of government funds for brain cancer research holds substantial promise for advancing adult malignant glioma therapeutics. This funding can significantly aid in the development of innovative treatments, tailored drug design, focusing on pyrimidine synthesis, and expediting orphan drug approvals. For example, in June 2023, the Australian Department of Health and Aged Care initiated the Australian Brain Cancer Mission, committing a fund of $136.66 million specifically aimed at supporting brain cancer research endeavors. The primary objective of this initiative is to double survival rates and enhance the overall quality of life for brain cancer patients, including those with anaplastic astrocytoma. Consequently, government funding geared towards brain cancer research stands as a pivotal driver propelling the adult malignant glioma therapeutics market.

Leading companies within the adult malignant glioma therapeutics market are actively engaged in the development of innovative products, notably small molecule targeted degraders, aimed at providing enhanced and dependable customer service. Small-molecule targeted degraders represent a class of drugs employing small molecules to induce the degradation of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, attained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 designed to treat glioblastoma (GBM). BEA-17 functions as a small-molecule targeted degrader targeting the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the pathogenesis of various cancers, including GBM. The drug works by degrading LSD1 and CoREST, leading to the reactivation of tumor suppressor genes and inhibiting the growth of cancer cells. This innovative approach holds promise in advancing treatment options within the adult malignant glioma therapeutics market.

In May 2024, Novartis, a Switzerland-based pharmaceutical company, acquired Mariana Oncology for $1 billion. This acquisition is intended to enhance Novartis's pipeline in radioligand therapies (RLTs) for various cancers, including potential applications for solid tumors like gliomas. Mariana Oncology, a US-based preclinical-stage biotechnology firm, focuses on developing therapeutics for gliomas.

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adult malignant glioma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The adult malignant glioma therapeutics market consists of revenues earned by entities by providing services such as resection, subtotal resection, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The adult malignant glioma therapeutics market consists of sales of temozolomide, bevacizumab, carmustine, and monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adult Malignant Glioma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adult malignant glioma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adult malignant glioma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adult malignant glioma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types
• 2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies
• 3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users
• Subsegments:
• 1) By Glioblastoma Multiforme: Standard Treatments; Experimental Therapies
• 2) By Anaplastic Astrocytoma: Chemotherapy Options; Targeted Therapies
• 3) By Anaplastic Oligodendroglioma: Radiation Therapy; Combination Therapies
• 4) By Anaplastic Oligoastrocytoma: Surgical Interventions; Adjuvant Therapies
• 5) By Other Types: Rare Gliomas; Emerging Therapies
• Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Allergan plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adult Malignant Glioma Therapeutics Market Characteristics

3. Adult Malignant Glioma Therapeutics Market Trends And Strategies

4. Adult Malignant Glioma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Adult Malignant Glioma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adult Malignant Glioma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adult Malignant Glioma Therapeutics Market Growth Rate Analysis
• 5.4. Global Adult Malignant Glioma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adult Malignant Glioma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adult Malignant Glioma Therapeutics Total Addressable Market (TAM)

6. Adult Malignant Glioma Therapeutics Market Segmentation

• 6.1. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glioblastoma Multiforme
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Anaplastic Oligoastrocytoma
• Other Types
• 6.2. Global Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Radiotherapy
• Other Therapies
• 6.3. Global Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Cancer And Radiation Therapy Centers
• Other End Users
• 6.4. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Glioblastoma Multiforme, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Treatments
• Experimental Therapies
• 6.5. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Astrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Options
• Targeted Therapies
• 6.6. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligodendroglioma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Combination Therapies
• 6.7. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Anaplastic Oligoastrocytoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Interventions
• Adjuvant Therapies
• 6.8. Global Adult Malignant Glioma Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Gliomas
• Emerging Therapies

7. Adult Malignant Glioma Therapeutics Market Regional And Country Analysis

• 7.1. Global Adult Malignant Glioma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adult Malignant Glioma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adult Malignant Glioma Therapeutics Market

• 8.1. Asia-Pacific Adult Malignant Glioma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adult Malignant Glioma Therapeutics Market

• 9.1. China Adult Malignant Glioma Therapeutics Market Overview
• 9.2. China Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adult Malignant Glioma Therapeutics Market

• 10.1. India Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adult Malignant Glioma Therapeutics Market

• 11.1. Japan Adult Malignant Glioma Therapeutics Market Overview
• 11.2. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adult Malignant Glioma Therapeutics Market

• 12.1. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adult Malignant Glioma Therapeutics Market

• 13.1. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adult Malignant Glioma Therapeutics Market

• 14.1. South Korea Adult Malignant Glioma Therapeutics Market Overview
• 14.2. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adult Malignant Glioma Therapeutics Market

• 15.1. Western Europe Adult Malignant Glioma Therapeutics Market Overview
• 15.2. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adult Malignant Glioma Therapeutics Market

• 16.1. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adult Malignant Glioma Therapeutics Market

• 17.1. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adult Malignant Glioma Therapeutics Market

• 18.1. France Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adult Malignant Glioma Therapeutics Market

• 19.1. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adult Malignant Glioma Therapeutics Market

• 20.1. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adult Malignant Glioma Therapeutics Market

• 21.1. Eastern Europe Adult Malignant Glioma Therapeutics Market Overview
• 21.2. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adult Malignant Glioma Therapeutics Market

• 22.1. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adult Malignant Glioma Therapeutics Market

• 23.1. North America Adult Malignant Glioma Therapeutics Market Overview
• 23.2. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adult Malignant Glioma Therapeutics Market

• 24.1. USA Adult Malignant Glioma Therapeutics Market Overview
• 24.2. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adult Malignant Glioma Therapeutics Market

• 25.1. Canada Adult Malignant Glioma Therapeutics Market Overview
• 25.2. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adult Malignant Glioma Therapeutics Market

• 26.1. South America Adult Malignant Glioma Therapeutics Market Overview
• 26.2. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adult Malignant Glioma Therapeutics Market

• 27.1. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adult Malignant Glioma Therapeutics Market

• 28.1. Middle East Adult Malignant Glioma Therapeutics Market Overview
• 28.2. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adult Malignant Glioma Therapeutics Market

• 29.1. Africa Adult Malignant Glioma Therapeutics Market Overview
• 29.2. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adult Malignant Glioma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adult Malignant Glioma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Adult Malignant Glioma Therapeutics Market Competitive Landscape
• 30.2. Adult Malignant Glioma Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bio-Rad Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Allergan plc Overview, Products and Services, Strategy and Financial Analysis

31. Adult Malignant Glioma Therapeutics Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Novartis AG
• 31.3. Bayer AG
• 31.4. Merck & Co Inc.
• 31.5. GlaxoSmithKline plc
• 31.6. Bristol-Myers Squibb Company
• 31.7. Abbott Laboratories
• 31.8. AstraZeneca plc
• 31.9. Eli Lilly and Company
• 31.10. Amgen Inc.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. GT Medical Technologies Inc.
• 31.13. Lupin Limited
• 31.14. Mylan NV
• 31.15. Sanofi SA

32. Global Adult Malignant Glioma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adult Malignant Glioma Therapeutics Market

34. Recent Developments In The Adult Malignant Glioma Therapeutics Market

35. Adult Malignant Glioma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Adult Malignant Glioma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adult Malignant Glioma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adult Malignant Glioma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer